CJC-1295 + Ipamorelin: why they are often discussed together

Two different receptors, two different entry points into the GH axis — and a research idea about what the two do together.

TL;DR

• CJC-1295 is a GHRH analog that binds the GHRH receptor on pituitary somatotrophs, while ipamorelin is a ghrelin/GHS-R agonist that binds a completely separate receptor — the ghrelin receptor (GHS-R1a).
• Older studies that gave GHRH together with earlier GH-releasing peptides found a larger GH pulse than either alone. The CJC-1295 and ipamorelin pairing rests on that mechanism; it is a research idea, not an established treatment.
• Ipamorelin is notable for its selectivity: unlike earlier GH secretagogues (GHRP-2, GHRP-6), it did not significantly raise cortisol in published studies in rats and pigs.

What it is

CJC-1295 (without DAC) is a modified GHRH analog — a synthetic version of growth-hormone-releasing hormone engineered for improved stability over natural GHRH. It binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary, triggering the cellular cascade that produces and releases GH.

Ipamorelin is a pentapeptide — five amino acids — developed as a selective growth hormone secretagogue. It binds the ghrelin receptor (GHS-R1a), which is a distinct receptor from GHRHR expressed on a partially overlapping population of pituitary cells. The ghrelin receptor pathway represents a second, parallel mechanism for stimulating GH release.

These are not two versions of the same mechanism. They are two different doors into the same room.

How it works

The GH secretagogue receptor (GHS-R1a) and the GHRH receptor (GHRHR) are distinct G-protein-coupled receptors that converge on GH secretion through separate intracellular signaling cascades. Research on GHRH given together with earlier GH-releasing peptides found a synergistic response — a GH pulse larger than what GHRH or a ghrelin agonist produced alone (Bowers, J Pediatr Endocrinol, 1993). That work predates CJC-1295 and did not test the two peptides discussed here.

Ipamorelin's selectivity was described in a pharmacological study by Raun and colleagues at Novo Nordisk, which compared ipamorelin's GH-stimulating effects to GHRP-2 and GHRP-6 in rats and pigs. In those animals, ipamorelin stimulated GH release at potencies comparable to the older GHRPs, but without the rise in ACTH and cortisol seen with the older GHRPs (Raun et al., European Journal of Endocrinology, 1998).

This selectivity is why ipamorelin draws attention. The finding comes from animal studies, and it does not show a health benefit in people.

Who asks about it

CJC-1295 + ipamorelin is one of the most frequently discussed peptide combinations in functional medicine and longevity contexts. People ask about it after seeing it mentioned online, and often want to understand the mechanism behind the pairing.

What the research says

The Raun et al. 1998 study remains the foundational pharmacological reference for ipamorelin's selectivity profile, conducted in rats and pigs with GH, cortisol, ACTH, and prolactin measurements. The authors described ipamorelin as "the first selective GH secretagogue."

CJC-1295's pharmacokinetics were established by Teichman et al. (2006) in a randomized, placebo-controlled study in healthy adults, demonstrating dose-dependent GH elevation and sustained IGF-1 increases following single administration, with a half-life of approximately 6–8 days for the DAC formulation; the non-DAC form is far shorter-acting (Teichman et al., JCEM, 2006).

A review of GH secretagogues found few long-term, rigorously controlled studies of them in people (Sigalos & Pastuszak, Sex Med Rev, 2018). The pairing of CJC-1295 with ipamorelin rests on the two-receptor mechanism described above, not on published trials of the two given together.

What to know

FDA has not approved CJC-1295 or ipamorelin, and FDA has not decided whether pharmacies may compound them (see the FDA status note on this page). The human research on each peptide is small, and the safety of the two given together has not been established in published trials. This page does not recommend using them together.

The Halftime POV

CJC-1295 and ipamorelin are discussed together because they act on two different receptors that both lead to growth hormone release. That mechanism is real, and the older research behind it is real. But the selectivity data for ipamorelin comes from rats and pigs, and the pair has not been tested together in published trials. Understanding why the pairing is discussed is not the same as evidence that it works or is safe.

Related reading:

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved.

Sources

• Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998.
• Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006.
• Bowers CY. GH releasing peptides--structure and kinetics. Journal of Pediatric Endocrinology, 1993.
• Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews, 2018.

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.